# MMRF CureCloud® Study: Patients and Researchers Collaborating Towards Cures

Anne Quinn Young, MPH, Erin Mensching, RN, BSN, OCN, Eva M. Lepisto, MA, MSc, Jennifer Rogers, BS, MS, April Cook, PhD, Caryn Rosenbaum, BS, Mary DeRome, BS, MSc, Michael Andreini, BS, George Mulligan, PhD, Hearn J. Cho, MD, PhD



## Introduction



Multiple myeloma (MM) is an **incurable** blood cancer affecting plasma cells



While MM is initially controlled with treatment, patients often **relapse** and develop multi-drug **resistance**, which requires regular use of new therapies to treat disease



**Precision medicine** targets myeloma subtypes resulting from genomic variations in a patients' myeloma cells and helps overcome multidrug resistance in MM



The MMRF CureCloud® Research Initiative (NCT03657251) is a trial designed to collect genomic data directly from patients with MM or smoldering MM to create a database of patient profiles and accelerate precision medicine for all patients

## Study Objectives



Create a resource of biospecimens and clinical data linked through the MMRF CureCloud® to accelerate a cure for MM by advancing precision medicine and informing treatment options



Enroll a **diverse** patient population to identify genomic and immune biomarkers that can be correlated with clinical outcomes and are relevant to every patient



Empower patients by making them **active participants** in research and keep them engaged and informed throughout the course of the study

### Status



Over 900 patients enrolled as of September 2022 Estimated study completion date: **July 31, 2026** 



Study contact: MMRF Patient Navigation Center 888-841-6673 • patientnavigator@themmrf.org



#### Methods



